NASDAQ:FATE - Fate Therapeutics Stock Price, Forecast & News

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company earned $2.43 million during the quarter, compared to analyst estimates of $1.75 million. Fate Therapeutics had a negative net margin of 900.24% and a negative return on equity of 48.94%. The business's revenue for the quarter was up 136.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.31) earnings per share. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Fate Therapeutics.

16 brokerages have issued twelve-month target prices for Fate Therapeutics' stock. Their forecasts range from $20.00 to $32.00. On average, they anticipate Fate Therapeutics' share price to reach $25.19 in the next twelve months. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

News articles about FATE stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include BioNTech (BNTX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI) and Editas Medicine (EDIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Rigel Pharmaceuticals (RIGL), Immunomedics (IMMU) and Crispr Therapeutics (CRSP).

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (14.84%), Millennium Management LLC (4.44%), State Street Corp (3.59%), Point72 Asset Management L.P. (1.56%), Pictet Asset Management Ltd. (1.48%) and Nikko Asset Management Americas Inc. (1.29%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Barclays PLC, Alps Advisors Inc., Partner Investment Management L.P., Doheny Asset Management CA, Voya Investment Management LLC and Metropolitan Life Insurance Co NY. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., State Street Corp and Endurant Capital Management LP. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $18.68.

Fate Therapeutics has a market capitalization of $1.41 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]